TNFRSF8 and lymphoma: Wang and colleagues also tested an anti-CD30 CAR T-cell in 18 patients with r/r CD30+ lymphoma (17 HL, 1 ALCL) and found mixed responses with a median progression-free survival of 6 months [115].